LLY Eli Lilly LLY · NYSE · Healthcare
SEC EDGAR ↗ SEC EDGAR Filings checked 23 Oct 2026, 16:23 UTC Financials checked 23 Oct 2026, 16:23 UTC
Some records were last checked more than 24 hours ago. These are the last verified records; check the official source for the latest filings.
Annual reporting period: 2025-01-01 — 2025-12-31 · USD
Annual revenue $65.18B Year over year +44.7%
Annual net income $20.64B Consolidated net income
Annual operating income — Standard fact unavailable
Operating margin — Operating income / revenue
Revenue over time ANNUAL
2016-12-31 · 21,222,100,000 USD
2016 $21.22B
2017-12-31 · 19,973,800,000 USD
2017 $19.97B
2018-12-31 · 21,493,300,000 USD
2018 $21.49B
2019-12-31 · 22,319,500,000 USD
2019 $22.32B
2020-12-31 · 24,539,800,000 USD
2020 $24.54B
2021-12-31 · 28,318,400,000 USD
2021 $28.32B
2022-12-31 · 28,541,400,000 USD
2022 $28.54B
2023-12-31 · 34,124,000,000 USD
2023 $34.12B
2024-12-31 · 45,043,000,000 USD
2024 $45.04B
2025-12-31 · 65,179,000,000 USD
2025 $65.18B Each bar is one fiscal year of revenue, ending on the date shown.
Income statement CONSOLIDATED Line 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 Revenue $65.18B $45.04B $34.12B $28.54B $28.32B $24.54B $22.32B $21.49B $19.97B $21.22B Cost of revenue $11.05B $8.42B $7.08B $6.63B $7.31B $5.48B $4.72B $4.68B $4.45B $5.71B Gross profitcomputed $54.13B $36.63B $27.04B $21.91B $21.01B $19.06B $17.6B $16.81B $15.53B $15.51B Research and development — — — $7.19B $6.93B $5.98B $5.6B $5.05B $5.1B $5.31B Selling, general and administrative $11.09B $8.59B $7.4B $6.44B $6.43B $6.12B $6.21B $5.98B $5.98B $6.53B Non-operating income $-571M $-219M $97M $-320.9M $-201.6M $1.17B $291.6M $145.6M $301.5M $112.8M Income tax expense $5.09B $2.09B $1.31B $561.6M $573.8M $1.04B $628M $529.5M $2.39B $636.4M Net income $20.64B $10.59B $5.24B $6.24B $5.58B $6.19B $8.32B $3.23B $-204.1M $2.74B Basic EPS 23.00 11.76 5.82 6.93 6.15 6.82 8.93 3.14 -0.19 2.59 Diluted EPS 22.95 11.71 5.80 6.90 6.12 6.79 8.89 3.13 -0.19 2.58 Diluted shares outstanding 0.90B 0.90B 0.90B 0.90B 0.91B 0.91B 0.94B 1.03B 1.05B 1.06B
Balance sheet CONSOLIDATED Line 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 Total assets $112.48B $78.72B $64.01B $49.49B $48.81B $46.63B $39.29B $43.91B $44.98B $38.81B Current assets $55.63B $32.74B $25.73B $18.03B $18.45B $17.46B $13.71B $20.55B $19.2B $15.1B Cash and equivalents $7.27B $3.27B $2.82B $2.07B $3.82B $3.66B $2.34B $7.32B $6.54B $4.58B Short-term investments — $154.8M $109.1M $144.8M $90.1M $24.2M $101M $88.2M $1.5B $1.46B Accounts receivable $17.76B $11.01B $9.09B $6.9B $6.67B $5.88B $4.55B $4.59B $4.55B $4.03B Inventory $13.74B $7.59B $5.77B $4.31B $3.89B $3.98B $3.19B $3.1B $4.46B $3.56B Property, plant and equipment $24.68B $17.1B $12.91B $10.14B $8.99B $8.68B $7.87B $8B $8.83B $8.25B Total liabilitiescomputed $85.94B $64.44B $53.23B $38.84B $39.83B $40.99B $36.68B $34.08B $33.39B $24.8B Current liabilities $35.23B $28.38B $27.29B $17.14B $15.05B $12.48B $11.78B $11.89B $14.54B $10.99B Accounts payable $5.38B $3.23B $2.6B $1.93B $1.67B $1.61B $1.41B $1.21B $1.41B $1.35B Long-term debt $40.87B $28.53B $18.32B $14.74B $15.35B $16.59B $13.82B $9.2B $9.94B $8.37B Shareholders' equity $26.54B $14.27B $10.77B $10.65B $8.98B $5.64B $2.61B $9.83B $11.59B $14.01B Retained earnings $24.47B $13.55B $10.31B $10.04B $8.96B $7.83B $4.92B $11.4B $13.89B $16.05B
Cash flow statement CONSOLIDATED Line 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 Operating cash flow $16.81B $8.82B $4.24B $7.59B $7.37B $6.5B $4.84B $5.52B $5.62B $4.85B Investing cash flow $-10.97B $-9.3B $-7.15B $-3.76B $-2.87B $-2.26B $-8.08B $1.91B $-3.78B $-3.14B Financing cash flow $-2.21B $1.23B $3.5B $-5.41B $-4.13B $-3.14B $-2.32B $-5.9B $142.6M $-559.8M Depreciation and amortisation $2B $1.77B $1.53B $1.52B $1.55B $1.32B $1.23B $1.61B $1.57B $1.5B Dividends paid $5.38B $4.68B $4.07B $3.54B $3.09B $2.69B $2.41B $2.31B $2.19B $2.16B Share buybacks $4.11B $2.5B $750M $1.5B $1.25B $500M $4.4B $4.15B $299.8M $600.1M
Key ratios COMPUTED HERE Line 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 Gross margin 83.0% 81.3% 79.2% 76.8% 74.2% 77.7% 78.8% 78.2% 77.7% 73.1% Net margin 31.7% 23.5% 15.4% 21.9% 19.7% 25.2% 37.3% 15.0% -1.0% 12.9% Return on equity 77.8% 74.2% 48.6% 58.6% 62.2% 109.8% 319.1% 32.9% -1.8% 19.5% Return on assets 18.4% 13.5% 8.2% 12.6% 11.4% 13.3% 21.2% 7.4% -0.5% 7.1% Asset turnover 0.58× 0.57× 0.53× 0.58× 0.58× 0.53× 0.57× 0.49× 0.44× 0.55× Current ratio 1.58× 1.15× 0.94× 1.05× 1.23× 1.40× 1.16× 1.73× 1.32× 1.37× Debt to equity 323.9% 451.5% 494.2% 364.7% 443.5% 726.6% 1,407.0% 346.7% 288.0% 177.0% Net debt $33.6B $25.26B $15.5B $12.67B $11.53B $12.93B $11.48B $1.88B $3.4B $3.79B Cash conversion cycle 376d 278d 261d 219d 197d 245d 212d 225d 333d 211d
Amounts are as filed. An em dash means that line was not reported, not that it is nil; rows marked “computed” and the whole key-ratios table are worked out here from those amounts.
About this record 10 fiscal years from 2016 to 2025, covering 30 statement lines, collected from SEC EDGAR. The most recent was confirmed on 2026-02-12.
2 lines here were not reported separately and follow by subtraction from lines that were. They are marked “computed” in the tables.
This page offers no investment view or forecast about Eli Lilly. The amounts are as the company filed them, the ratios follow from those amounts, and no currency is converted.
Run these figures through the calculators · Reading guides · Methodology